IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Shares of Puma Biotechnology PBYI have witnessed a sharp increase in the past three months, driven by investor optimism ...

Danaher is seeing strong Biotechnology growth as bioprocessing demand rises, with equipment orders up more than 30% and core ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the ...

The total funding comprises US$1 million in angel investment and a US$4 million seed round. The seed financing round was led by Wavemaker Ventures, with participation by SEEDS, further supported by ...

A bill before Congress would amend the COINS Act, which restricts American investment in sensitive technologies abroad, to ...

Sacramento’s permanent R&D tax credit cap puts biomedical innovation at risk. Read the urgent 2026 sector report to protect ...

U.S. drug companies are accelerating licensing deals with Chinese pharmaceutical companies to take advantage of China’s ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026.